KNX-101 is a 15-lipoxygenase (15-LOX; ALOX15) inhibitor which is under development for the treatment of chronic agitation and aggression as well as acute and chronic pain. Whereas its predecessor KNX-100 (SOC-1) is described as a "short-acting" 15-LOX inhibitor, KNX-101 is said to be a "long-acting" 15-LOX inhibitor. Both KNX-100 and KNX-101 produce antiaggressive effects without causing sedation in the chronic social isolation model in rodents, whereas the atypical antipsychotic risperidone only reduces aggression at doses that also induce sedation. KNX-101 is under development by Kinoxis Therapeutics. As of January 2026, it is in the preclinical research stage of development.
See also List of investigational agitation drugs List of investigational aggression drugs List of investigational analgesics KNX-100 (SOC-1)
References
External links Science - Kinoxis Therapeutics Pipeline - Kinoxis Therapeutics